There is still only a very small number of pharmaceuticals that according to the relevant admission data contain nanomaterials. Among them are drugs for:
- treatment of tumor diseases (e.g. Caelyx, Mepact, Abraxane, Rapamune, Renagel)
- chronic hepatitis (e.g. PegIntron, Pegasys)
- acromegaly (e.g. Somavert)
- multiple sclerosis (e.g. Copaxone)
- febrile neuropathy (e.g. Neulasta)
- Morbus Crohn (e.g. Cimzia)
- age-related macular degeneration (AMD) (e.g. Macugen)
- increased LDL-C values and diabetes mellitus type 2 (e.g. Welchol)
- MRT contrast agents (in-vivo diagnostics) with iron oxide nanoparticles (e.g. Feridex)
- parenteral iron (e.g. Cosmofer, Ferrlecit)
Besides, several authors refer to drugs containing nanoscale molecules and particles:
- liposomes (Caelyx, Myocet)
- polymer-protein conjugates (PegIntron, Somavert)
- polymeric substances (Copaxone)
Source : German Bundestag, Federal printed matter 17/3771.
